Integra LifeSciences to Acquire J&J’s Codman Neurosurgery
Integra LifeScience Holdings Corp. has announced its intention to acquire Johnson & Johnson’s Codman Neurosurgery for $1.05 billion. Codman specializes in devices for advanced hydrocephalus, neuro-critical care and operative neurosurgery. Integra anticipates that if J&J accepts the binding offer it will become a leader in neurosurgical devices, as its portfolio will complement Integra’s line of products for tissue ablation, dural repair and cranial stabilization.
“This proposed transformational acquisition of Codman Neurosurgery creates compelling value for our shareholders, employees and patients,” said Peter Arduini, president and CEO of Integra, in a release. “Its innovative portfolio and global reach will enable us to enhance our position in the neurosurgery market, while also building a global infrastructure that will benefit Integra as a whole. We look forward to welcoming the more than 600 Codman Neurosurgery employees to the Integra team.”
Related Articles
-
Johnson & Johnson holds firm that it will continue to accelerate in the innovation department over the next year.
-
Bloomberg reports that the world’s largest healthcare company Johnson & Johnson is in talks with Cardinal Health Inc. to sell its Cordis unit. The unit may fetch as much as $2 billion in a sale, according to the story.
-
The deal is part of Johnson & Johnson’s strategy to grow its vision care business.
-
The healthcare giant reported worldwide medical devices sales of $27.5 billion for the full-year 2014, a decrease of 3.4 percent versus the prior year.
